Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Additional therapeutic options are needed for patients with lung cancer with HER2 activating mutations, including exon 20 insertions. Sevabertinib shows activity against ERBB2-encoded HER2 exon 20 insertions in preclinical models of lung cancer, corroborated by early data from a phase 1/2 clinical trial.
Authors
- Kirstin Petersen
- Kristýna Kotýnková (ORCID: https://orcid.org/0000-0003-2066-9505)
- Sven Golfier
- Heidi Greulich (ORCID: https://orcid.org/0000-0001-5571-9862)
- Markus Berger (ORCID: https://orcid.org/0000-0001-6676-6090)
- Bethany Kaplan
- Timothy A. Lewis (ORCID: https://orcid.org/0000-0001-9748-9575)
- Paolo Grassi (ORCID: https://orcid.org/0000-0002-5691-2768)
- Andrew D. Cherniack (ORCID: https://orcid.org/0000-0003-0470-0111)
- Knut Eis (ORCID: https://orcid.org/0000-0003-2881-8798)
- Herbert H. Loong (ORCID: https://orcid.org/0000-0002-6607-1106)
- Kōichi Goto (ORCID: https://orcid.org/0000-0002-3023-2510)
- Dominik Rüttinger
- Sawyer Andersen
- Jérémie Mortier (ORCID: https://orcid.org/0000-0001-8707-3867)
- R.C. Hillig (ORCID: https://orcid.org/0000-0001-6267-7250)
- Franziska Siegel
- Matthew Meyerson (ORCID: https://orcid.org/0000-0002-9133-8108)
- Gizem Karsli Uzunbas
- Ulf Boemer
- D.R. Denney
- Sybil M. Genther Williams
- Daniel Korr
- Stephan Siegel (ORCID: https://orcid.org/0000-0002-4913-1146)
- Volker Schulze (ORCID: https://orcid.org/0000-0002-0158-1789)
- H Tomono
Institutions
- Broad Institute (US)
- eBay (Ireland) (IE)
- Bayer (United States) (US)
- Chinese University of Hong Kong (HK)
- Meyer Children's Hospital (IT)
- Dana-Farber Cancer Institute (US)
- Bayer (Italy) (IT)
- Nuvisan (Germany) (DE)
- National Cancer Center Hospital East (JP)
- Bayer (Germany) (DE)
Publication Details
- Journal
- Cancer Discovery
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1158/2159-8290.cd-25-0605
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 6.07